BFRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Biofrontera Inc (BFRI) is not a strong buy for a beginner, long-term investor at this time. While there are some positive technical indicators and favorable news developments, the company's weak financial performance, lack of significant trading trends, and absence of proprietary trading signals suggest a cautious approach. The investor may consider monitoring the stock for further developments or improved financial performance before making a decision.
The technical indicators show a mixed picture. The MACD is positive and expanding, suggesting bullish momentum. The RSI is in the neutral zone at 65.117, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above its pivot level of 0.844, with resistance levels at 0.932 and 0.987.
Favorable U.S. Patent Trial and Appeal Board ruling, which benefits Biofrontera in the photodynamic therapy market.
Expansion plans into non-melanoma skin cancers and acne treatments.
Increased gross margin to 70.74%, up 54.18% YoY.
Revenue dropped significantly by -22.46% YoY in Q3
EPS declined by -36.73% YoY, indicating weaker profitability.
Net income remains negative at -6.65M, despite a slight improvement YoY.
In Q3 2025, Biofrontera's revenue dropped by -22.46% YoY to $6.99M. Net income improved slightly but remains negative at -$6.65M. EPS decreased by -36.73% YoY to -0.62. However, gross margin increased significantly to 70.74%, up 54.18% YoY, showing some operational efficiency.
No data available for analyst ratings or price target changes.
